Abstract Library

#3935 Single-cell sequencing reveals the heterogeneity of pancreatic neuroendocrine tumors under the pattern of genomic instability and histological grading

Introduction: Non-functional pancreatic neuroendocrine tumor (NF-Pan-NET) is a kind of highly heterogeneous tumors. Histological grading is the key factors affecting the prognosis of patients and instructive in guiding treatment and assessing recurrence in NF-Pan-NET. 90% of NF-Pan-NET are grade G1 or G2, leading to an unpredictable clinical course that varies from indolent to highly malignant. Approximately one-third of patients without CNV alteration and the prognosis of these patients are better than that of patients with CNV alteration. Therefore, probing the heterogeneity of tumors based on histological grading and CNV variation is crucial.

Conference:

Presenting Author: Ye Z

Authors: Ye Z, Zhou C, Xu X, Chen J, Yu X,

Keywords: Pancreatic neuroendocrine tumor, single-cell sequencing, genomic instability, histological grading,

#3747 Characteristics of Pancreatic Neuroendocrine Tumors (PNET) patients treated with Peptide Receptor Radionuclide Therapy (PRRT) in two Canadian centers – A real-world evidence study

Introduction: PRRT is a standard practice for treatment of metastatic midgut neuroendocrine tumors. PNET patients who progressed on prior therapy are also considered for PRRT if accessible via special access.

Conference:

Presenting Author: Tsvetkova E

Authors: Tsvetkova E, Welch S, Laidley D, Sachdeva R, Goodwin R,

Keywords: Pancreatic Neuroendocrine Tumor, Peptide Receptor Radionuclide Therapy, Real World Experience,

#3445 The epidemiology of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in the North-East of England and a systematic review of literature

Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare, slow-growing malignancies with unknown aetiology and an increasing incidence was observed globally. With limited research on GEP-NET epidemiology, the reasons behind incidence disparities across countries remain unclear. Whether this increase was a true phenomenon or confounded by factors including diagnostic advancement, environment, and classification evolution needs further enquiry.

Conference:

Presenting Author:

Authors: Chu G, Robinson S, Etherson K, McNally R,

Keywords: Gastroenteropancreatic neuroendocrine tumor, Epidemiology, Incidence,

#3442 Surgical management of patients with sporadic Zollinger-Ellison Syndrome: An ACHBT and GTE study

Introduction: The only curative treatment of sporadic gastrinoma is complete surgical resection, but its surgical management remain controversial.

Conference:

Presenting Author: Gaujoux S

Authors: Gaujoux S, Robin L, Sauvanet A, Walter T, Naja H,

Keywords: gastrinoma, surgery, pancreaticoduodenectomy, lymphadenectomy,

#3273 LIBRETTO-531: Selpercatinib vs standard of care in patients (pts) with multikinase inhibitor-naïve advanced or metastatic RET-mutant (mut) medullary thyroid cancer (MTC)

Introduction: Multikinase inhibitors (MKI) are approved for MTC; however, their efficacy in RETmut MTC is limited due to incomplete RET inhibition and significant toxicity. Selpercatinib (LOXO-292), a highly selective and potent FDA approved inhibitor of RET alterations including M918T, MKI resistance-associated V804M, and others, showed robust, durable clinical activity with a tolerable profile in pts with RETmut MTC in the Phase 1/2 LIBRETTO-001 study.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Leboulleux S, Robinson B, Hoff A, Brose M, Wirth L,

Keywords: RET alteration, medullary thyroid cancer (MTC), phase 3 trial, selpercatinib,